What we do Lasa Supergenerics Limited manufactures and trades pharmaceuticals and active pharmaceutical ingredients (APIs), specializing in veterinary anthelmintic APIs with strong global marketing presence. |
Founded in 2,016 |
Market share Largest production capacity for veterinary anthelmintic APIs in India, strong demand globally with high entry barriers for key products. |
Problem solved Provides essential veterinary and human healthcare APIs ensuring efficient, integrated production and reliable supply of critical medicines. |
Top clients or who we serve Serves pharmaceutical companies in veterinary and human sectors worldwide, focusing on B2B markets across developing countries. |
Key management Dr. Omkar Herlekar (Chairman & Managing Director), Mr. Umesh Shankar Pawar (Executive Director), Mrs. Varsha Pravin Joshi (Chief Financial Officer) |
Our journey and innovations Vertical integration from discovery to delivery with multiple patented manufacturing processes; merged with Harishree Aromatics recently to expand capabilities. |
Where we operate Manufacturing in Maharashtra, India with exports to multiple developing countries globally. |
Top products or what we offer Veterinary anthelmintic APIs such as Oxyclozanide; extensive range of pharmaceutical APIs for animal and human healthcare. |
Top brands Oxyclozanide API - globally demanded with strong entry barriers; other proprietary APIs protected by patents. |
Raw materials needed Chemical intermediates for catalyst chemistry and API synthesis. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue primarily from recurring bulk API manufacturing contracts with some cyclical fluctuations. |
Our industry position Leader in veterinary API manufacturing in India with growing international footprint and strong R&D innovations. |
Financial highlights FY2024 revenue of Rs.104.33 Cr; net loss due to depreciation and finance costs but operating profit increased to Rs.2.27 Cr. |
Geographical revenue split - |
Order book - |
Whats driving growth Strong global demand for veterinary APIs, strategic brownfield capacity expansion, and enhancement of export markets. |
Our future plans Capacity expansion at Chiplun facility, broadening export footprint, and continued patent-driven product innovation. |
Our green promise Focuses on energy conservation and safety in manufacturing; adheres to regulatory environmental standards. |
Our people and values High-performance culture supporting employee growth, with policies ensuring workplace safety and diversity. |
Key challenges ahead Pending insolvency litigation with bank, managing debt settlement, and sustaining profitability. |
Interesting facts Holds multiple patents for API manufacturing processes; strong entry barriers for blockbuster veterinary products. |
Risks and strategy Legal challenges with creditors; strategy focuses on amicable resolution and operational efficiency enhancement. |
